TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling

Journal of Molecular Signaling

Volumn 5, Issue , 2010, Pages

  Campbell, Paul M ^a   Boufaied, Nadia ^b   Fiordalisi, James J ^a   Cox, Adrienne D ^a   Falardeau, Pierre ^b   Der, Channing J ^a   Gourdeau, Henriette ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Thallion Pharmaceuticals Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI PACA; BACTERIA (MICROORGANISMS); MUS;

EID: 77958527538     PISSN: None     EISSN: 17502187     Source Type: Journal    
DOI: 10.1186/1750-2187-5-18     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20:1218-1249. 10.1101/gad.1415606, 16702400.
3. Talar-Wojnarowska R, Malecka-Panas E. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit 2006, 12:RA186-193.
4. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002, 2:897-909. 10.1038/nrc949, 12459728.
5. Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS, Vaitkevicius VK, Crissman JD, Sarkar FH. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol 1997, 21:127-143. 10.1007/BF02821608, 9209954.
6. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, Kloppel G. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992, 102:230-236.
7. Barbacid M. ras genes. Annu Rev Biochem 1987, 56:779-827. 10.1146/annurev.bi.56.070187.004023, 3304147.
8. Reuther GW, Der CJ. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol 2000, 12:157-165. 10.1016/S0955-0674(99)00071-X, 10712923.
9. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta 2005, 1756:127-144.
10. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
11. Rivera F, Lopez-Tarruella S, Vega-Villegas ME, Salcedo M. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 2009, 35:335-339. 10.1016/j.ctrv.2008.11.007, 19131170.
12. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966. 10.1200/JCO.2006.07.9525, 17452677.
13. Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, Becouarn Y, Montoto-Grillot C, Gourgou-Bourgade S, Adenis A, . FNCLCC-FFCD PRODIGE Group Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010, 28:4010. FNCLCC-FFCD PRODIGE Group.
14. McAlpine JB, Bachmann BO, Piraee M, Tremblay S, Alarco AM, Zazopoulos E, Farnet CM. Microbial genomics as a guide to drug discovery and structural elucidation: ECO-02301, a novel antifungal agent, as an example. J Nat Prod 2005, 68:493-496. 10.1021/np0401664, 15844935.
15. McAlpine JB, Banskota AH, Charan RD, Schlingmann G, Zazopoulos E, Piraee M, Janso J, Bernan VS, Aouidate M, Farnet CM, et al. Biosynthesis of diazepinomicin/ECO-4601, a Micromonospora secondary metabolite with a novel ring system. J Nat Prod 2008, 71:1585-1590. 10.1021/np800376n, 18722414.
16. Zazopoulos E, Huang K, Staffa A, Liu W, Bachmann BO, Nonaka K, Ahlert J, Thorson JS, Shen B, Farnet CM. A genomics-guided approach for discovering and expressing cryptic metabolic pathways. Nat Biotechnol 2003, 21:187-190. 10.1038/nbt784, 12536216.
17. Zhang L, Demain AL. Natural products: drug discovery and therapeutic medicine. 2005, Totowa, N.J.: Humana Press.
18. Boufaied N, Wioland MA, Falardeau P, Gourdeau H. TLN-4601, a novel anticancer agent, inhibits Ras signaling post Ras prenylation and before MEK activation. Anticancer Drugs 2010, 21:543-552. 10.1097/CAD.0b013e328337f373, 20220516.
19. Benz CC, Brandt BH, Zanker KS. Gene diagnostics provide new insights into breast cancer prognosis and therapy. Gene 1995, 159:3-7. 10.1016/0378-1119(95)00147-X, 7607570.
20. Gasparini G, Boracchi P, Bevilacqua P, Mezzetti M, Pozza F, Weidner N. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res Treat 1994, 29:59-71. 10.1007/BF00666182, 7912568.
21. Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WL, Foekens JA. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 1994, 29:73-83. 10.1007/BF00666183, 8018964.
22. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1:117-123. 10.1016/S1535-6108(02)00039-9, 12086869.
23. Lim KH, O'Hayer K, Adam SJ, Kendall DS, Campbell PM, Der CJ, Counter CM. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol 2006, 16:1-10. 10.1016/j.cub.2006.10.023, 16401419.
24. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007, 67:2098-2106. 10.1158/0008-5472.CAN-06-3752, 17332339.
25. Campbell PM, Lee KM, Ouellette MM, Kim HJ, Groehler AL, Khazak V, Der CJ. Ras-driven transformation of human nestin-positive pancreatic epithelial cells. Methods Enzymol 2008, 439:451-465. full_text, 18374182.
26. Yip-Schneider MT, Lin A, Barnard D, Sweeney CJ, Marshall MS. Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression. Int J Oncol 1999, 15:271-279.
27. Yip-Schneider MT, Lin A, Marshall MS. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun 2001, 280:992-997. 10.1006/bbrc.2001.4243, 11162624.
28. Barnard D, Diaz B, Hettich L, Chuang E, Zhang XF, Avruch J, Marshall M. Identification of the sites of interaction between c-Raf-1 and Ras-GTP. Oncogene 1995, 10:1283-1290.
29. Chuang E, Barnard D, Hettich L, Zhang XF, Avruch J, Marshall MS. Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues. Mol Cell Biol 1994, 14:5318-5325. 359051, 8035810.
30. Nassar N, Horn G, Herrmann C, Block C, Janknecht R, Wittinghofer A. Ras/Rap effector specificity determined by charge reversal. Nat Struct Biol 1996, 3:723-729. 10.1038/nsb0896-723, 8756332.
31. Pumiglia K, Chow YH, Fabian J, Morrison D, Decker S, Jove R. Raf-1 N-terminal sequences necessary for Ras-Raf interaction and signal transduction. Mol Cell Biol 1995, 15:398-406. 231979, 7799948.
32. Weitman S, Marty J, Jolivet J, Locas C, Von Hoff DD. The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res 2000, 6:1574-1578.
33. Gourdeau H, McAlpine JB, Ranger M, Simard B, Berger F, Beaudry F, Farnet CM, Falardeau P. Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand. Cancer Chemother Pharmacol 2008, 61:911-921. 10.1007/s00280-007-0544-2, 17622531.
34. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310. 10.1038/sj.onc.1210422, 17496923.
35. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554. 10.1016/0092-8674(88)90571-5, 2453289.
36. Ishino K, Fukazawa H, Shikano M, Ohba M, Kuroki T, Uehara Y. Enhancement of anchorage-independent growth of human pancreatic carcinoma MIA PaCa-2 cells by signaling from protein kinase C to mitogen-activated protein kinase. Mol Carcinog 2002, 34:180-186. 10.1002/mc.10063, 12203369.
37. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988, 16:7773-7782. 10.1093/nar/16.16.7773, 338489, 3047672.
38. Yeh JJ, Der CJ. Targeting signal transduction in pancreatic cancer treatment. Expert Opin Ther Targets 2007, 11:673-694. 10.1517/14728222.11.5.673, 17465725.
39. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2:243-247. 10.1016/S1535-6108(02)00122-8, 12242156.
40. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22. 10.1038/nrc969, 12509763.
41. Mitin N, Rossman KL, Der CJ. Signaling interplay in Ras superfamily function. Curr Biol 2005, 15:R563-574. 10.1016/j.cub.2005.07.010, 16051167.
42. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M, Wigler MH. Multiple Ras functions can contribute to mammalian cell transformation. Cell 1995, 80:533-541. 10.1016/0092-8674(95)90507-3, 7867061.
43. Kloog Y, Cox AD. Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs. Semin Cancer Biol 2004, 14:253-261. 10.1016/j.semcancer.2004.04.004, 15219618.
44. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003, 22:8999-9006. 10.1038/sj.onc.1207111, 14663478.
45. Baccarini M. An old kinase on a new path: Raf and apoptosis. Cell Death Differ 2002, 9:783-785. 10.1038/sj.cdd.4401070, 12107820.
46. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005, 7:533-545. 10.1016/j.ccr.2005.04.030, 15950903.
47. Eckert LB, Repasky GA, Ülkü AS, McFall A, Zhou H, Sartor CI, Der CJ. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 2004, 64:4585-4592. 10.1158/0008-5472.CAN-04-0396, 15231670.
48. Ülkü AS, Schäfer R, Der CJ. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells. Mol Cancer Res 2003, 1:1077-1088.
49. Mason W, Belanger K, Nicholas GA, Vallieres I, Mathieu D, Desjardins A, Kavan P, Omuro AM, and Reymond D. A phase II trial of TLN-4601 in patients with glioblastoma multiforme (GBM) at first progression. J Clin Oncol 2010, 28:2094. 10.1200/JCO.2009.26.2758, 20308668.
50. Lee KM, Nguyen C, Ulrich AB, Pour PM, Ouellette MM. Immortalization with telomerase of the Nestin-positive cells of the human pancreas. Biochem Biophys Res Commun 2003, 301:1038-1044. 10.1016/S0006-291X(03)00086-X, 12589817.
51. Taylor SJ, Shalloway D. Cell cycle-dependent activation of Ras. Curr Biol 1996, 6:1621-1627. 10.1016/S0960-9822(02)70785-9, 8994826.